Just one year after Mylan’s pricing controversy, the company is yet again the subject of federal investigation. The Federal Trade Commission has issued a request for information about whether Epipen’s many patent changes effectively shielded it from generic competition. In addition to the FTC investigation, Mylan is involved in a Justice Department investigation into fixed-drug pricing, though Mylan has not been named as the subject of that particular probe. Read the full article here.